title: More on aprepitant for erlotinib-induced pruritus.
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.forename: Benoit
authors.initials: B
authors.lastname: Blanchet
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000077608:Aprepitant; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D056687:Off-Label Use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077608:Aprepitant; D000069347:Erlotinib Hydrochloride